ATE529445T1 - Biokinetik zur schnellen beseitigung von polypeptiden - Google Patents

Biokinetik zur schnellen beseitigung von polypeptiden

Info

Publication number
ATE529445T1
ATE529445T1 AT08863248T AT08863248T ATE529445T1 AT E529445 T1 ATE529445 T1 AT E529445T1 AT 08863248 T AT08863248 T AT 08863248T AT 08863248 T AT08863248 T AT 08863248T AT E529445 T1 ATE529445 T1 AT E529445T1
Authority
AT
Austria
Prior art keywords
polypeptide
methods
polypeptides
biokinetics
amino acid
Prior art date
Application number
AT08863248T
Other languages
English (en)
Inventor
Christofer Lendel
Elin Gunneriusson
Malin Lindborg
Brian Duh-Lan Lee
Jason William Castle
Faisal Ahmed Syud
Michael Ernest Marino
Original Assignee
Gen Electric
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Electric filed Critical Gen Electric
Application granted granted Critical
Publication of ATE529445T1 publication Critical patent/ATE529445T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08863248T 2007-12-19 2008-12-17 Biokinetik zur schnellen beseitigung von polypeptiden ATE529445T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/002,972 US8937047B2 (en) 2007-12-19 2007-12-19 Biokinetics of fast-clearing polypeptides
PCT/EP2008/067774 WO2009077569A1 (en) 2007-12-19 2008-12-17 Biokinetics of fast-clearing polypeptides

Publications (1)

Publication Number Publication Date
ATE529445T1 true ATE529445T1 (de) 2011-11-15

Family

ID=40591871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08863248T ATE529445T1 (de) 2007-12-19 2008-12-17 Biokinetik zur schnellen beseitigung von polypeptiden

Country Status (7)

Country Link
US (1) US8937047B2 (de)
EP (1) EP2231706B3 (de)
JP (1) JP5745275B2 (de)
CN (1) CN101952314B (de)
AT (1) ATE529445T1 (de)
ES (1) ES2375018T7 (de)
WO (1) WO2009077569A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124725B2 (en) * 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
EP2077272A1 (de) * 2007-12-21 2009-07-08 Affibody AB Polypeptid-Bibliothek mit vorbestimmtem Gerüst
US9187535B2 (en) * 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
US8937047B2 (en) * 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
EP2072525A1 (de) * 2007-12-21 2009-06-24 Affibody AB Neue Polypeptide mit Bindungsaffinität für HER2
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
US10861978B2 (en) 2012-04-02 2020-12-08 Samsung Display Co., Ltd. Display device
CN112870390B (zh) * 2021-01-29 2022-04-22 四川大学华西医院 一种镓68标记的亲合体蛋白pet显像剂及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US6673559B1 (en) 1989-12-27 2004-01-06 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Met proto-oncogene and a method for predicting breast cancer progression
US6271364B1 (en) * 1999-02-23 2001-08-07 Amgen Inc. Analogs of NT-3
EP1009762A2 (de) 1997-08-06 2000-06-21 ZymoGenetics, Inc. Lipocalinhomologen
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
EP2617736A1 (de) 2007-09-28 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Anti-Glypican-3-Antikörper mit verbesserter Kinetik in Plasma
US8124725B2 (en) * 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
US8937047B2 (en) * 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides

Also Published As

Publication number Publication date
EP2231706B1 (de) 2011-10-19
WO2009077569A1 (en) 2009-06-25
EP2231706B3 (de) 2012-07-18
JP2011509926A (ja) 2011-03-31
EP2231706A1 (de) 2010-09-29
JP5745275B2 (ja) 2015-07-08
ES2375018T7 (es) 2013-02-13
CN101952314B (zh) 2016-04-20
US20090180954A1 (en) 2009-07-16
ES2375018T3 (es) 2012-02-24
US8937047B2 (en) 2015-01-20
CN101952314A (zh) 2011-01-19

Similar Documents

Publication Publication Date Title
ATE529445T1 (de) Biokinetik zur schnellen beseitigung von polypeptiden
ES2535084T3 (es) Proteínas N-glicosiladas recombinantes procedentes de células procariotas
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
MX2018005512A (es) Agentes de union de esclerostina.
ES2379283T3 (es) Proteínas de unión a albúmina sérica
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
WO2008066583A3 (en) Cell-free synthesis of proteins containing unnatural amino acids
PE20091004A1 (es) Proteinas de union a antigenos c-fms humanos
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
BRPI0416544A (pt) proteìna de ligação de gag
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
HK1206763A1 (en) Charged nutritive fragments, proteins and methods
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
GB2462761A (en) Protein formulation
WO2006073976A3 (en) Compositions, methods, and kits for enhancing protein expression, solubility and isolation
ATE498683T1 (de) Leptin antagonisten
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
ATE549346T1 (de) Chemische modifikation von proteinen
DE602007012053D1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties